[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,378,675
  • Shares Outstanding, K 165,263
  • Annual Sales, $ 943,710 K
  • Annual Income, $ -381,390 K
  • EBIT $ -352 M
  • EBITDA $ -346 M
  • 60-Month Beta 0.36
  • Price/Sales 10.20
  • Price/Cash Flow N/A
  • Price/Book 19.59

Options Overview Details

View History
  • Implied Volatility 50.12% (+2.45%)
  • Historical Volatility 87.44%
  • IV Percentile 69%
  • IV Rank 45.54%
  • IV High 74.24% on 08/20/25
  • IV Low 29.96% on 05/07/26
  • Expected Move (DTE 3) 1.95 (3.53%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 6,746
  • Volume Avg (30-Day) 5,525
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 106,424
  • Open Int (30-Day) 84,095
  • Expected Range 53.24 to 57.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.09
  • Number of Estimates 8
  • High Estimate $-0.88
  • Low Estimate $-1.20
  • Prior Year $0.70
  • Growth Rate Est. (year over year) -255.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.54 +1.05%
on 07/14/26
86.74 -36.47%
on 07/08/26
-18.17 (-24.79%)
since 06/12/26
3-Month
54.54 +1.05%
on 07/14/26
86.74 -36.47%
on 07/08/26
-21.65 (-28.20%)
since 04/14/26
52-Week
40.03 +37.67%
on 08/07/25
86.74 -36.47%
on 07/08/26
+12.56 (+29.52%)
since 07/14/25

Most Recent Stories

More News
An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

DNLI : 23.33 (-11.90%)
IONS : 55.40 (-2.38%)
NAMS : 33.83 (+1.65%)
BIIB : 195.58 (-6.43%)
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints;...

IONS : 55.40 (-2.38%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 165.85 (-2.14%)
ALNY : 283.56 (-1.56%)
IONS : 55.40 (-2.38%)
BBIO : 83.50 (+0.51%)
PFE : 24.27 (-0.86%)
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint -- and now have legal rights worth protecting. Levi & Korsinsky...

IONS : 55.40 (-2.38%)
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people...

IONS : 55.40 (-2.38%)
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a...

IONS : 55.40 (-2.38%)
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.

IONS : 55.40 (-2.38%)
Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures...

ALK : 46.72 (-0.17%)
SNDK : 1,771.72 (+5.84%)
FDXF : 146.10 (-1.53%)
PSKY : 9.29 (-2.72%)
STX : 878.52 (+2.08%)
WDC : 563.73 (+1.47%)
AMD : 554.21 (+3.71%)
UPS : 113.45 (+0.50%)
SPY : 752.40 (+0.43%)
MU : 983.16 (+4.93%)
ALNY : 283.56 (-1.56%)
AAL : 15.85 (-2.82%)
Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.47%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.55%. September E-mini S&P futures...

SNDK : 1,771.72 (+5.84%)
TRI : 93.15 (-1.21%)
FDXF : 146.10 (-1.53%)
PSKY : 9.29 (-2.72%)
STX : 878.52 (+2.08%)
WDC : 563.73 (+1.47%)
AMD : 554.21 (+3.71%)
UPS : 113.45 (+0.50%)
SPY : 752.40 (+0.43%)
META : 660.97 (+0.65%)
ADSK : 207.78 (-2.09%)
MU : 983.16 (+4.93%)
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen...

IONS : 55.40 (-2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 59.54
2nd Resistance Point 58.72
1st Resistance Point 57.74
Last Price 55.40
1st Support Level 55.94
2nd Support Level 55.12
3rd Support Level 54.14

See More

52-Week High 86.74
Fibonacci 61.8% 68.90
Fibonacci 50% 63.38
Fibonacci 38.2% 57.87
Last Price 55.40
52-Week Low 40.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.